0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prognostic value and biological function of LRRN4 in colorectal cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Several nervous and nerve-related biomarkers have been detected in colorectal cancer (CRC) and can contribute to the progression of CRC. However, the role of leucine-rich repeat neuronal 4 (LRRN4), a recently identified neurogenic marker, in CRC remains unclear.

          Methods

          We examined the expression and clinical outcomes of LRRN4 in CRC from TCGA-COREAD mRNA-sequencing datasets and immunohistochemistry in a Chinese cohort. Furthermore, colony formation, flow cytometry, wound healing assays and mouse xenograft models were used to investigate the biological significance of LRRN4 in CRC cell lines with LRRN4 knockdown or overexpression in vitro and in vivo. In addition, weighted coexpression network analysis, DAVID and western blot analysis were used to explore the potential molecular mechanism.

          Results

          We provide the first evidence that LRRN4 expression, at both the mRNA and protein levels, was remarkably high in CRC compared to controls and positively correlated with the clinical outcome of CRC patients. Specifically, LRRN4 was an independent prognostic factor for progression-free survival and overall survival in CRC patients. Further functional experiments showed that LRRN4 promoted cell proliferation, cell DNA synthesis and cell migration and inhibited apoptosis. Knockdown of LRRN4 can correspondingly decrease these effects in vitro and can significantly suppress the growth of xenografts. Several biological functions and signaling pathways were regulated by LRRN4, including proteoglycans in cancer, glutamatergic synapse, Ras, MAPK and PI3K. LRRN4 knockdown resulted in downregulation of Akt, p-Akt, ERK1/2 and p-ERK1/2, the downstream of the Ras/MAPK signaling pathway, overexpression of LRRN4 leaded to the upregulation of these proteins.

          Conclusions

          Our results suggest that LRRN4 could be a biological and molecular determinant to stratify CRC patients into distinct risk categories, and mechanistically, this is likely attributable to LRRN4 regulating several malignant phenotypes of neoplastic cells via RAS/MAPK signal pathways.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12935-022-02579-x.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Microenvironmental regulation of tumor progression and metastasis.

          Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis. Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence. However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis. Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer. Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.

            The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms for controlling cell survival, differentiation, proliferation, metabolism, and motility in response to extracellular cues. Components of these pathways were among the first to be discovered when scientists began cloning proto-oncogenes and purifying cellular kinase activities in the 1980s. Ras-ERK and PI3K-mTOR were originally modeled as linear signaling conduits activated by different stimuli, yet even early experiments hinted that they might intersect to regulate each other and co-regulate downstream functions. The extent of this cross-talk and its significance in cancer therapeutics are now becoming clear. Copyright © 2011 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The MAPK pathway across different malignancies: a new perspective.

              The mitogen-activated protein kinase/extracellular signal-regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple signaling events in which information coalesces at this important nodal pathway point. This pathway is tightly regulated under normal conditions by phosphatases and bidirectional communication with other pathways, like the protein kinase B/mammalian target of rapamycin (AKT/m-TOR) pathway. Recent evidence indicates that the MAPK/ERK signaling node can function as a tumor suppressor as well as the more common pro-oncogenic signal. The effect that predominates depends on the intensity of the signal and the context or tissue in which the signal is aberrantly activated. Genomic profiling of tumors has revealed common mutations in MAPK/ERK pathway components, such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF). Currently approved for the treatment of melanoma, inhibitors of BRAF kinase are being studied alone and in combination with inhibitors of the MAPK and other pathways to optimize the treatment of many tumor types. Therapies targeted toward MAPK/ERK components have various response rates when used in different solid tumors, such as colorectal cancer and ovarian cancer. Understanding the differential nature of activation of the MAPK/ERK pathway in each tumor type is critical in developing single and combination regimens, because different tumors have unique mechanisms of primary and secondary signaling and subsequent sensitivity to drugs.
                Bookmark

                Author and article information

                Contributors
                179566264@qq.com
                chuanwen.fan@liu.se
                2018324020002@stu.scu.edu.cn
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                19 April 2022
                19 April 2022
                2022
                : 22
                : 158
                Affiliations
                [1 ]GRID grid.411304.3, ISNI 0000 0001 0376 205X, College of Medicine, , Chengdu University of Traditional Chinese Medicine, ; Chengdu, 610000 China
                [2 ]GRID grid.415440.0, Department of Oncology, , Hospital of Chengdu University of Traditional Chinese Medicine, ; Chengdu, 610000 China
                [3 ]GRID grid.412901.f, ISNI 0000 0004 1770 1022, Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, , West China Hospital, Sichuan University, ; Chengdu, 610000 China
                [4 ]GRID grid.13291.38, ISNI 0000 0001 0807 1581, Department of Gastrointestinal, Bariatric and Metabolic Surgery, and Research Center for Nutrition, Metabolism and Food Safety, West China-PUMC CC.C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, , Sichuan University, ; Chengdu, 610000 China
                [5 ]GRID grid.488387.8, Department of Oncology, , Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, ; Luzhou, 646000 China
                [6 ]GRID grid.5640.7, ISNI 0000 0001 2162 9922, Department of Oncology and Department of Biomedical and Clinical Sciences, , Linköping University, ; 58183 Linköping, Sweden
                [7 ]Cancer Center, The General Hospital of Western Theater Command, Chengdu, 610000 China
                Author information
                http://orcid.org/0000-0003-1047-8190
                Article
                2579
                10.1186/s12935-022-02579-x
                9020117
                35440048
                ec14d609-5b7b-4ab2-9e26-813f744c449b
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 23 October 2021
                : 8 April 2022
                Funding
                Funded by: Nature Science Foundation of China
                Award ID: 81972592
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100013365, West China Hospital, Sichuan University;
                Award ID: ZYGD20007
                Award ID: ZYJC18011
                Award Recipient :
                Funded by: Space Medical Experiment Project of China Manned Space Program
                Award ID: HYZHXM01004
                Award Recipient :
                Categories
                Primary Research
                Custom metadata
                © The Author(s) 2022

                Oncology & Radiotherapy
                colorectal cancer,neurogenic biomarker,leucine-rich repeat neuronal 4,prognosis,ras/mapk signal pathways

                Comments

                Comment on this article